Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adults with Acute Myeloid Leukemia Older Than Age 60

Phuong T Vo, Brenda M. Sandmaier, Megan Othus, Naveed Ali, Eduardo Rodríguez-Arbolí, Corentin Orvain, Chris Davis, Ryan S. Basom, Rainer F. Storb, Roland B. Walter

Blood (2024) 144 (Supplement 1): 7314.

https://doi.org/10.1182/blood-2024-206221

Published: 2024

Journal Articles

Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study

Blood (2024) 144 (Supplement 1): 3167.

https://doi.org/10.1182/blood-2024-199055

Published: 2024

Journal Articles

Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms

Zi Yun Ng, Laurane Cottin, Damien Luque Paz, Corentin Orvain, Kamel Laribi, Jean-Christophe Ianotto, Eric Lippert, Alesia Khan, Daniel Lock, Valerie Ugo, Claire Harrison, Jennifer O'Sullivan

Blood (2024) 144 (Supplement 1): 485.

https://doi.org/10.1182/blood-2024-201326

Published: 2024

Journal Articles

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Blood (2024) 144 (Supplement 1): 478.

https://doi.org/10.1182/blood-2024-198903

Published: 2024

Journal Articles

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Blood (2024) 144 (Supplement 1): 58.

https://doi.org/10.1182/blood-2024-205592

Published: 2024

Journal Articles

Thromboembolism in Individuals with High-Oxygen-Affinity Hemoglobins - Systematic Review of the Literature

Marie Laloi, Agathe Gouband, Damien Luque-Paz, Marianne Schwarz, Aline Schmidt, Valerie Ugo, Hunault-Berger Mathilde, Loic Garcon, Corentin Orvain

Blood (2024) 144 (Supplement 1): 5226.

https://doi.org/10.1182/blood-2024-204536

Published: 2024

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Blood (2024) 144 (Supplement 1): 4903.

https://doi.org/10.1182/blood-2024-201251

Published: 2024

Journal Articles

Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Blood (2024) 144 (Supplement 1): 731.

https://doi.org/10.1182/blood-2024-198614

Published: 2024

Journal Articles

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Blood (2024) 144 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2024-199110

Published: 2024

Journal Articles

Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy

Mathilde Bastien, Maxime Jullien, Nicolas Vallet, Aline Schmidt, Tony Marchand, Amandine Le Bourgeois, Alice Garnier, Sophie Vantyghem, Aude-Marie Fourmont, Corentin Orvain, Marc Bernard, Thierry Guillaume, Jean-Baptiste Méar, Mathilde Hunault, Emmanuel Gyan, Pierre Peterlin, Patrice Chevallier

Blood (2024) 144 (Supplement 1): 1531.

https://doi.org/10.1182/blood-2024-201589

Published: 2024

Journal Articles

Impact of Socioeconomic Disparities on Outcomes in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Daniel J Olivieri, Megan Othus, Corentin Orvain, Eduardo Rodríguez-Arbolí, Filippo Milano, Brenda M. Sandmaier, Irum Khan, Chris Davis, Ryan S. Basom, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 3809.

https://doi.org/10.1182/blood-2023-181244

Published: 2023

Journal Articles

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2864.

https://doi.org/10.1182/blood-2023-190128

Published: 2023

Journal Articles

Autoimmune Cytopenia Associated with Indolent B-Cell Clones: A Large Multicentric Cohort Study

Blood (2023) 142 (Supplement 1): 800.

https://doi.org/10.1182/blood-2023-178535

Published: 2023

Journal Articles

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Corentin Orvain, Sarah Bertoli, Pierre Peterlin, Yohan Desbrosses, Pierre-Yves Dumas, Alexandre Iat, Marie Anne Hospital, Martin Carre, Emmanuelle Tavernier, Anne Bouvier, Audrey Bidet, Sylvie Tondeur, Florian Renosi, Eric Delabesse, Arnaud Pigneux, Hunault-Berger Mathilde, Christian Recher

Blood (2023) 142 (Supplement 1): 421.

https://doi.org/10.1182/blood-2023-184848

Published: 2023

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Blood (2023) 142 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2023-185751

Published: 2023

Journal Articles

Association between Molecular Profile and Outcome after Intensive Chemotherapy in Patients > 60 Years with Adverse Cytogenetic Risk and/or Secondary Acute Myeloid Leukemia - a Filo Study

Corentin Orvain, Anne Bouvier, Audrey Bidet, Pierre-Yves Dumas, Sarah Bertoli, Odile Blanchet, Sylvain Thepot, Aline Schmidt, Arnaud Pigneux, Eric Delabesse, Christian Recher, Hunault-Berger Mathilde

Blood (2023) 142 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2023-184815

Published: 2023

Journal Articles

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Blood (2023) 142 (Supplement 1): 445.

https://doi.org/10.1182/blood-2023-181571

Published: 2023

Journal Articles

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Sylvain Garciaz, Sarah Bertoli, David A Sallman, Justine Decroocq, Pierre-Yves Dumas, Amine Belhabri, Corentin Orvain, Gaspar Aspas Requena, Celestine Simand, Kamel Laribi, Martin Carré, Alberto Santagostino, Ludovic Gabellier, Marie Anne Hospital, Ariane Mineur, Arnaud Pigneux, Norbert Vey, Christian Récher

Blood (2023) 142 (Supplement 1): 161.

https://doi.org/10.1182/blood-2023-185437

Published: 2023

Journal Articles

Role of Measurable Residual Disease (MRD) Testing for the Prediction of Late Relapses Following Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia

Naveed Ali, Othus Megan, Eduardo Rodríguez-Arbolí, Corentin Orvain, Filippo Milano, Brenda M. Sandmaier, Chris Davis, Ryan S. Basom, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 4308.

https://doi.org/10.1182/blood-2023-183117

Published: 2023

Journal Articles

Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML

Corentin Orvain, Naveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, Filippo Milano, Brenda M. Sandmaier, Bart L. Scott, Frederick R. Appelbaum, Roland B. Walter

Blood (2023) 142 (Supplement 1): 4315.

https://doi.org/10.1182/blood-2023-188633

Published: 2023

NARROW

Allogeneic Hematopoietic Cell Transplantation (HCT) for Adults with Acute Myeloid Leukemia Older Than Age 60

Outcome of Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms Ineligible for Intensive Chemotherapy or Allogeneic Hematopoietic Cell Transplantation Treated By Azacitidine Alone or in Combination - a FIM Study

Dynamics of Calr variant Allele Frequency with Therapy in Myeloproliferative Neoplasms

18-Months Follow-up of the Trial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting

Real-World Multicenter Evaluation of Venetoclax and Azacitidine for Molecular Relapse after First Line Intensive Chemotherapy in Patients with NPM1 Mutated or Core Binding Factor (CBF) AML. a Filo Study

Thromboembolism in Individuals with High-Oxygen-Affinity Hemoglobins - Systematic Review of the Literature

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Determinants of Isolated CNS Relapse in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. from Graall-2005 to -2014 Trials

Switch of Asparaginase Formulation Based on Antibody Monitoring in Adults with Philadelphia-Negative Adult Lymphoblastic Leukemia. Results of the Graall-2014 Trial

Inflammatory Biomarkers Predict Response and Survival in Chemotherapy-Ineligible and Untreated Acute Myeloid Leukemia Patients Receiving Venetoclax-Azacytidine As Front-Line Therapy

Impact of Socioeconomic Disparities on Outcomes in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia

Autoimmune Cytopenia Associated with Indolent B-Cell Clones: A Large Multicentric Cohort Study

Molecular Relapse after First-Line Intensive Therapy in Patients with Core-Binding Factor and NPM1 -Mutated Acute Myeloid Leukemia - a Filo Study

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Association between Molecular Profile and Outcome after Intensive Chemotherapy in Patients > 60 Years with Adverse Cytogenetic Risk and/or Secondary Acute Myeloid Leukemia - a Filo Study

T rial of Imatinib after Ponatinib Induction (TIPI) in the Front-Line Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Setting. Report of the First Therapeutic Sequence

Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study

Role of Measurable Residual Disease (MRD) Testing for the Prediction of Late Relapses Following Allogeneic Hematopoietic Cell Transplantation in Adult Acute Myeloid Leukemia

Relative Prognostic Value of Flow Cytometric Measurable Residual Disease before Allogeneic Hematopoietic Cell Transplantation for Adults with MDS/AML or AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only